GIGAGEN

In News

Grifols ponies up $80M for polyclonal antibody biotech GigaGen - Fierce Biotech

Fierce Biotech - Mar 10, 2021

GigaGen Doses First Patient in Phase 1 Trial of GIGA-2339, a Potential Functional Cure for Chronic Hepatitis B - Contagion Live

Contagion Live - Nov 25, 2024

Innovating Biothreat Therapies: An Interview with Head of GigaGen - The Clinical Trial Vanguard

The Clinical Trial Vanguard - Oct 17, 2024

GigaGen doses first subject in Phase I advanced solid tumour trial - Clinical Trials Arena

Clinical Trials Arena - May 21, 2024

Waisman Biomanufacturing partners with GigaGen to manufacture new COVID-19 drug - UW–Madison News

UW–Madison News - Sep 09, 2020

Recombinant polyclonal antibodies for viral diseases - Drug Discovery News

Drug Discovery News - Mar 25, 2024

GigaGen Works to Develop Passive, Convalescent COVID-19 Therapy - BioSpace

BioSpace - Mar 30, 2020

Unleashing the potential of lab-grown recombinant polyclonal antibodies - Drug Target Review

Drug Target Review - Jul 17, 2024

Phase 1 clinical trial cleared for HBV antibody GIGA-2339 - European AIDS Treatment Group

European AIDS Treatment Group - Aug 07, 2024

GigaGen Announces New Office Space in South San Francisco - PR Newswire

PR Newswire - Jan 23, 2018

GigaGen's New Contract with BARDA for Polyclonal Antibody Development - Contagion Live

Contagion Live - Oct 04, 2024

Grifols' GigaGen garners up to $135M from BARDA to tackle botulinum biothreat - Fierce Biotech

Fierce Biotech - Oct 03, 2024

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment